<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264743</url>
  </required_header>
  <id_info>
    <org_study_id>2013MM002B</org_study_id>
    <secondary_id>2013-002094-22</secondary_id>
    <nct_id>NCT02264743</nct_id>
  </id_info>
  <brief_title>Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy</brief_title>
  <acronym>OPTIMISE</acronym>
  <official_title>Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chelsea and Westminster NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ultra-low-dose oral E2/D will have more beneficial effects than trans-dermal HRT on lipids
      and insulin resistance in postmenopausal women, whilst adverse effects on coagulation will be
      avoided.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following screening for eligibility, women will be studied at baseline and then randomized to
      one of two groups:

      Group A administered Femoston Conti - oral oestradiol 17β 0.5 mg/dydrogesterone 2.5 mg daily
      for the duration of the treatment phase (24 weeks)

      Group B administered ½ Evorel Conti patches - trans-dermal Estradiol 25 mcg/norethisterone
      acetate 85 mcg (½ Evorel Conti patches) daily for the duration of the treatment phase (24
      weeks).

      Studies will be repeated after 6 months of therapy at the follow up visit.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombin Generation IU/DL</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
    <time_frame>6 months</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL</measure>
    <time_frame>6 months</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL</measure>
    <time_frame>6 months</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-Dimers</measure>
    <time_frame>6 months</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APC resistance</measure>
    <time_frame>6 months</time_frame>
    <description>&gt;2 or &lt;2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrinogen</measure>
    <time_frame>6 months</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor V11</measure>
    <time_frame>6 months</time_frame>
    <description>U/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAI-1 protein</measure>
    <time_frame>6 months</time_frame>
    <description>nq/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>6 months</time_frame>
    <description>pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>6 months</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Venous Thrombosis</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Femoston Conti 0.5mg/2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultra low dose, film-coated 17β-estradiol (as hemihydrate) 0.5mg &amp; dydrogesterone 2.5 mg
Once a day
The duration is six months.
Drug intervention: Estradiol&amp;DydrogesteronevsOestradiol&amp;Norethisterone acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVOREL® CONTI transdermal patches</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EVOREL CONTI is a transdermal self adhesive patch which is 0.1 mm in thickness and each patch releases 50mcg of oestradiol and 170mcg of norethisterone acetate over 24 hours .
The Evorel Conti patch is cut in half and applied to the lower part of the body for 3.5 days (delivering approx 25mcg of oestradiol over 24 hours ) this is replaced every 3.5 days .
The duration is six months.
Drug intervention: Estradiol&amp;DydrogesteronevsOestradiol&amp;Norethisterone acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femoston Conti</intervention_name>
    <description>Ultra-low-dose oral E2/D [Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg] oral Femoston Conti 0.5mg Estradiol&amp;Dydrogesterone vs Oestradiol&amp;Norethisterone acetate</description>
    <arm_group_label>Femoston Conti 0.5mg/2.5mg</arm_group_label>
    <other_name>Femoston Conti 0.5mg/2.5mg film-coated tablets versus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVOREL® CONTI</intervention_name>
    <description>Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch</description>
    <arm_group_label>EVOREL® CONTI transdermal patches</arm_group_label>
    <other_name>Evorel Conti transdermal patch 25 mcg transdermal dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy and postmenopausal woman who have had a normal ultrasound result

          -  Aged 40 - 60 years

          -  At least 1 year post last menstrual period (per participant report)

          -  BMI 18 - 32

          -  Normal mammogram within 2 years of study commencement

          -  Continue on any concomitant medications without any change during the study give
             informed consent

        Exclusion Criteria:

          -  Estrogen or androgen therapy during preceding 3 months

          -  Use of hormone implants during the preceding 12 months

          -  Have received any medications which may interfere with the study (SSRI, antiandrogens,

          -  PDE5 inhibitors, DHEA, SERMS)

          -  Have a significant psychiatric disorder

          -  Have a history of breast or oestrogen dependent cancer

          -  Have diabetes, thrombo-embolic disorders (recent MI angina DVT varicose veins or
             recurrent DVT), cardiovascular disease, liver disease any condition affecting
             carbohydrate metabolism, uncontrolled hypertension and uncontrolled hyperlipidaemia

          -  Untreated endometrial hyperplasia

          -  Dubin-Johnson syndrome and Rotor syndrome

          -  Undiagnosed vaginal bleeding

          -  Women who have had a hysterectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Stevenson, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Stevenson, MBBS</last_name>
    <phone>0207 351 8112</phone>
    <email>j.stevenson@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Gerval, MBBS</last_name>
    <phone>07734386042</phone>
    <email>m.gerval@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chelsea and Westminster NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Panay, MBBS, MRCOG</last_name>
      <phone>0203 331 8112</phone>
      <email>n.panay@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Nick Panay, MBBS,MRCOG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton and Harefield NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Stevenson, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Panay, MBBS, MRCOG</last_name>
      <phone>0203 331 8112</phone>
      <email>n.panay@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Nick Panay, MBBS, MRCOG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

